Chlamydia pneumoniae Infection and Risk for Lung Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: We evaluated the relationship of Chlamydia pneumoniae infection with prospective lung cancer risk using traditional serologic markers [microimmunoflourescence (MIF) IgG and IgA antibodies] and Chlamydia heat shock protein-60 (CHSP-60) antibodies, a marker for chronic chlamydial infection. Methods: We conducted a nested case-control study (593 lung cancers and 671 controls) within the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (N = 77,464). Controls were matched to cases by age, sex, randomization year, follow-up time, and smoking (pack-years of smoking, time since quitting). We assessed C. pneumoniae seropositivity and endpoint antibody titers (IgG and IgA against C. pneumoniae elementary bodies and IgG against CHSP-60). Results: C. pneumoniae seropositivity by microimmunoflourescence IgG or IgA antibodies was not associated with lung cancer [odds ratio of 0.88 and 95% confidence interval (95% CI) of 0.69-1.13 for IgG; odds ratio of 0.98 and 95% CI of 0.75-1.27 for IgA]. In contrast, individuals seropositive for CHSP-60 IgG antibodies had significantly increased lung cancer risk (odds ratio, 1.30; 95% CI, 1.02-1.67), and risk increased with increasing antibody titers (P trend = 0.006). CHSP-60–related risk did not differ significantly by lung cancer histology, follow-up time, or smoking. CHSP-60 seropositivity was associated with increased risk 2 to 5 years before lung cancer diagnosis (odds ratio, 1.77; 95% CI, 1.16-2.71; P trend = 0.006), thus arguing against reverse causality. Conclusions: CHSP-60 seropositivity and elevated antibody titers were associated with significantly increased risk for subsequent lung cancer, supporting an etiologic role for C. pneumoniae infection in lung carcinogenesis. Impact: Our results highlight the potential for lung cancer risk reduction through treatments targeted toward C. pneumoniae infections and chronic pulmonary inflammation. Cancer Epidemiol Biomarkers Prev; 19(6); 1498–505. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Glass, A., Keogh, J. P., Meyskens, F. L., Valanis, B., Williams, J. H., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1550 · Cited by 1,255
Validation of a self-administered diet history questionnaire using multiple diet records
Block, G., Woods, M., Potosky, A., & Clifford, C. (1990) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(90)90099-b · Cited by 1,197
Research works printed but not linked: 33
- Alberg, 2005, Epidemiology of lung cancer: looking to the future, J Clin Oncol, 23, 3175, 10.1200/JCO.2005.10.462 · DOI · Paper page
- Parkin, 2005, Global cancer statistics, 2002, CA Cancer J Clin, 55, 74, 10.3322/canjclin.55.2.74 · DOI · Paper page
- Sun, 2007, Lung cancer in never smokers—a different disease, Nat Rev Cancer, 7, 778, 10.1038/nrc2190 · DOI · Paper page
- Engels, 2008, Inflammation in the development of lung cancer: epidemiological evidence, Expert Rev Anticancer Ther, 8, 605, 10.1586/14737140.8.4.605 · DOI · Paper page
- Ballaz, 2003, The potential contributions of chronic inflammation to lung carcinogenesis, Clin Lung Cancer, 5, 46, 10.3816/CLC.2003.n.021 · DOI · Paper page
- Hahn, 2002, Chlamydia pneumoniae as a respiratory pathogen, Front Biosci, 7, e66, 10.2741/hahn · DOI
- Laurila, 1997, Serological evidence of an association between Chlamydia pneumoniae infection and lung cancer, Int J Cancer, 74, 31, 10.1002/(SICI)1097-0215(19970220)74:1<31::AID-IJC6>3.0.CO;2-1 · DOI · Paper page
- Jackson, 2000, Association of Chlamydia pneumoniae immunoglobulin A seropositivity and risk of lung cancer, Cancer Epidemiol Biomarkers Prev, 9, 1263
- Littman, 2004, Chlamydia pneumoniae infection and risk of lung cancer, Cancer Epidemiol Biomarkers Prev, 13, 1624, 10.1158/1055-9965.1624.13.10 · DOI · Paper page
- Littman, 2005, Chlamydia pneumoniae and lung cancer: epidemiologic evidence, Cancer Epidemiol Biomarkers Prev, 14, 773, 10.1158/1055-9965.EPI-04-0599 · DOI · Paper page
- Kocazeybek, 2003, Chronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: a case-control study, J Med Microbiol, 52, 721, 10.1099/jmm.0.04845-0 · DOI
- Smith, 2008, Lack of association between serum antibodies of Chlamydia pneumoniae infection and the risk of lung cancer, Int J Cancer, 123, 2469, 10.1002/ijc.23814 · DOI
- Koh, 2005, Lack of association between chronic Chlamydophila pneumoniae infection and lung cancer among nonsmoking Chinese women in Singapore, Int J Cancer, 114, 502, 10.1002/ijc.20745 · DOI
- Littman, 2004, Interlaboratory reliability of microimmunofluorescence test for measurement of Chlamydia pneumoniae-specific immunoglobulin A and G antibody titers, Clin Diagn Lab Immunol, 11, 615
- Dowell, 2001, Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada), Clin Infect Dis, 33, 492, 10.1086/322632 · DOI · Paper page
- Peeling, 1999, Heat shock protein expression and immunity in chlamydial infections, Infect Dis Obstet Gynecol, 7, 72, 10.1155/S1064744999000149 · doi:10.1155/s1064744999000149
- Stephens, 2003, The cellular paradigm of chlamydial pathogenesis, Trends Microbiol, 11, 44, 10.1016/S0966-842X(02)00011-2 · DOI · Paper page
- Peeling, 1998, Antibody response to the 60-kDa chlamydial heat-shock protein is associated with scarring trachoma, J Infect Dis, 177, 256, 10.1086/517367 · doi:10.1086/517367
- Peeling, 1999, Antibody response to the chlamydial heat-shock protein 60 in an experimental model of chronic pelvic inflammatory disease in monkeys (Macaca nemestrina), J Infect Dis, 180, 774, 10.1086/314919 · doi:10.1086/314919
- Eckert, 1997, Prevalence and correlates of antibody to chlamydial heat shock protein in women attending sexually transmitted disease clinics and women with confirmed pelvic inflammatory disease, J Infect Dis, 175, 1453, 10.1086/516479 · doi:10.1086/516479
- Bax, 2004, Chlamydia trachomatis heat shock protein 60 (cHSP60) antibodies in women without and with tubal pathology using a new commercially available assay, Sex Transm Infect, 80, 415, 10.1136/sti.2004.009167 · DOI
- Tiitinen, 2006, Chlamydia trachomatis and chlamydial heat shock protein 60-specific antibody and cell-mediated responses predict tubal factor infertility, Hum Reprod, 21, 1533, 10.1093/humrep/del014 · doi:10.1093/humrep/del014
- Mahdi, 2002, Serum immunoglobulin G antibodies to chlamydial heat shock protein 60 but not to human and bacterial homologs are associated with coronary artery disease, Circulation, 106, 1659, 10.1161/01.CIR.0000031567.10814.D8 · DOI
- Biasucci, 2003, Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes, Circulation, 107, 3015, 10.1161/01.CIR.0000078632.76653.6C · DOI
- Prorok, 2000, Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Control Clin Trials, 21, 273, 10.1016/S0197-2456(00)00098-2 · DOI · Paper page
- Hayes, 2005, Methods for etiologic and early marker investigations in the PLCO trial, Mutat Res, 592, 147, 10.1016/j.mrfmmm.2005.06.013 · DOI
- Wang, 1979, Formalinized Chlamydia trachomatis organisms as antigen in the micro-immunofluorescence test, J Clin Microbiol, 10, 259, 10.1128/jcm.10.2.259-261.1979 · doi:10.1128/jcm.10.2.259-261.1979
- Suzuki, 2006, Serum heat shock protein 70 levels and lung cancer risk: a case-control study nested in a large cohort study, Cancer Epidemiol Biomarkers Prev, 15, 1733, 10.1158/1055-9965.EPI-06-0005 · DOI
- Chaturvedi, C-reactive protein and risk of lung cancer, J Clin Oncol
- Siscovick, 2000, Collaborative multidisciplinary workshop report: the role of epidemiology studies in determining a possible relationship between Chlamydia pneumoniae infection and atherothrombotic diseases, J Infect Dis, 181, S430, 10.1086/315598 · doi:10.1086/315598
- Siscovick, 2000, Chlamydia pneumoniae and atherosclerotic risk in populations: the role of seroepidemiology, J Infect Dis, 181, S417, 10.1086/315623 · DOI
- Fong, 2002, Chlamydial heat-shock protein-60 antibody and correlation with Chlamydia pneumoniae in atherosclerotic plaques, J Infect Dis, 186, 1469, 10.1086/344730 · DOI
- Koyi, 2001, An association between chronic infection with Chlamydia pneumoniae and lung cancer. A prospective 2-year study, APMIS, 109, 572, 10.1034/j.1600-0463.2001.d01-177.x · DOI · Paper page
Cited by
Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer
Farrell, J. J., Zhang, L., Zhou, H., Chia, D., Elashoff, D., Akin, D., Paster, B. J., Joshipura, K., & Wong, D. T. W. (2012) · Gut · doi:10.1136/gutjnl-2011-300784 · Cited by 662
Lung Cancer in Never Smokers: Clinical Epidemiology and Environmental Risk Factors
Samet, J. M., Avila-Tang, E., Boffetta, P., Hannan, L. M., Olivo-Marston, S., Thun, M. J., & Rudin, C. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0376 · Cited by 566
Airway microbiota is associated with upregulation of the PI3K pathway in lung cancer
Tsay, J.-C. J., Wu, B. G., Badri, M. H., Clemente, J. C., Shen, N., Meyn, P., Li, Y., Yie, T.-A., Lhakhang, T., Olsen, E., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201710-2118oc · Cited by 448
Autophagy as a molecular target for cancer treatment
Kocaturk, N. M., Akkoc, Y., Kig, C., Bayraktar, O., Gozuacik, D., & Kutlu, O. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.011 · Cited by 387
Previous Lung Diseases and Lung Cancer Risk: A Systematic Review and Meta-Analysis
Brenner, D. R., McLaughlin, J. R., & Hung, R. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017479 · Cited by 343
Metadata
- Authors
- Chaturvedi, A. K., Gaydos, C. A., Agreda, P., Holden, J. P., Chatterjee, N., Goedert, J. J., Caporaso, N. E., & Engels, E. A.
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2010-06-01
- Volume
- 19
- Issue
- 6
- Pages
- 1498-1505
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- OpenAlex
- W2128959177
- Cited by
- 150
- References
- 2
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chlamydia pneumoniae Infection and Risk for Lung Cancer. https://app.cochat.ai/papers/10.1158/1055-9965.epi-09-1261
- The paper
- Chaturvedi, A. K., Gaydos, C. A., Agreda, P., Holden, J. P., Chatterjee, N., Goedert, J. J., Caporaso, N. E., & Engels, E. A. (2010). Chlamydia pneumoniae Infection and Risk for Lung Cancer. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-09-1261
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.